Simvastatin Information
Simvastatin is a medication included in the class of drugs called statins. Statin drugs are used together with diet and exercise to reduce blood levels of low-density lipoprotein (LDL) cholesterol ("bad cholesterol").
Simvastatin is sold as a single-ingredient generic medication and under the brand-name Zocor. It is also sold in combination with ezetimibe as Vytorin, and niacin as Simcor.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this sheet.
Related Information
- Information on Statins
- FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury
- FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs
- FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone
- FDA Drug Safety Podcast for Healthcare Professionals: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone
- FDA announces new safety recommendations for high-dose simvastatin
- FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury
- FDA Drug Safety Podcast for Healthcare Professionals: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury
- FDA: Limit Use of 80 mg Simvastatin
- FDA Statement on the AIM-HIGH Trial
- FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor, (simvastatin) and increased risk of muscle injury
- FDA Warns about Increased Risk of Muscle Injury with Zocor
- Statement to Healthcare Professionals on the ACCORD Lipid Trial from the FDAâs Center for Drug Evaluation and Research
- Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
- Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial (8/21/08)
- Information for Healthcare Professionals - Simvastatin (marketed as Zocor and generics), Ezetimibe/Simvastatin (marketed as Vytorin), Niacin extended-release /Simvastatin (marketed as Simcor), used with Amiodarone (Cordarone, Pacerone)
- Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)